Ubs Asset Management Americas Inc Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Ubs Asset Management Americas Inc

$345 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $39.8 Million - $41.8 Million	-274,722 Reduced 81.11%	63,992 $9.67 Million
Q2 2022 Aug 12, 2022	BUY	$83.14 - $145.99 $23.1 Million - $40.6 Million	278,098 Added 458.79%	338,714 $49.4 Million
Q1 2022 May 16, 2022	BUY	$110.08 - $142.92 $466,629 - $605,837	4,239 Added 7.52%	60,616 $7.19 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $145,605 - $216,780	1,460 Added 2.66%	56,377 $7.77 Million
Q3 2021 Nov 15, 2021	BUY	$98.85 - $138.91 $55,652 - $78,206	563 Added 1.04%	54,917 $7.63 Million
Q2 2021 Aug 16, 2021	BUY	$65.78 - $105.02 $148,070 - $236,400	2,251 Added 4.32%	54,354 $5.28 Million
Q1 2021 May 14, 2021	BUY	$64.07 - $91.75 $161,328 - $231,026	2,518 Added 5.08%	52,103 $3.56 Million
Q4 2020 Mar 01, 2021	BUY	$65.07 - $98.24 $301,078 - $454,556	4,627 Added 10.29%	49,585 $4.25 Million
Q3 2020 Nov 13, 2020	BUY	$59.04 - $77.95 $16,708 - $22,059	283 Added 0.63%	44,958 $2.92 Million
Q2 2020 Aug 14, 2020	SELL	$29.01 - $74.23 $186,969 - $478,412	-6,445 Reduced 12.61%	44,675 $3.27 Million
Q1 2020 May 15, 2020	SELL	$27.51 - $57.29 $62,860 - $130,907	-2,285 Reduced 4.28%	51,120 $1.74 Million
Q4 2019 Feb 14, 2020	SELL	$40.86 - $57.65 $5.73 Million - $8.09 Million	-140,353 Reduced 72.44%	53,405 $2.91 Million
Q3 2019 Nov 14, 2019	BUY	$37.38 - $49.47 $558,531 - $739,180	14,942 Added 8.36%	193,758 $8.08 Million
Q2 2019 Aug 15, 2019	BUY	$39.79 - $67.01 $6.84 Million - $11.5 Million	171,904 Added 2487.04%	178,816 $0
Q4 2018 Feb 13, 2019	BUY	$29.75 - $42.9 $9,282 - $13,384	312 Added 4.73%	6,912 $255,000
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $216,414 - $283,800	6,600 New	6,600 $0

Others Institutions Holding BHVN

# of Institutions

Shares Held

785K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account